公开(公告)号：US12117448B2

公开(公告)日：2024-10-15

申请号：US16867560

申请日：2020-05-05

Applicant: Children's Medical Center Corporation

Inventor： Randolph Watnick

IPC: G01N33/574 ,  A61K38/00 ,  A61K38/17 ,  A61K45/06 ,  A61K48/00 ,  C07K14/475

CPC classification number: G01N33/574 ,  A61K38/1709 ,  A61K45/06 ,  C07K14/475 ,  A61K38/00 ,  A61K48/00 ,  G01N2800/56

Abstract: The invention relates to isolated peptides and chimeric polypeptides derived from Saposin A that have anti-angiogenic activity. These peptides are small, consisting essentially of at least 10 consecutive amino acid residues from the 31st-50th amino acid residue of Saposin A. The invention also relates to the use of these isolated peptides and chimeric polypeptides in compositions for the treatment, prevention, and inhibition of angiogenesis-related diseases and disorders such as cancer and cancer metastasis.

公开(公告)号：US20240319191A1

公开(公告)日：2024-09-26

申请号：US18731669

申请日：2024-06-03

Applicant: Quest Diagnostics Investments LLC

Inventor： Daniel Jones ,  Kevin J. Arvai ,  Ya-Hsuan Hsu

IPC: G01N33/574 ,  C12Q1/6886

CPC classification number: G01N33/57419 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N2333/47 ,  G01N2333/916 ,  G01N2800/52 ,  G01N2800/56

Abstract: Methods and kits for detecting alternating spatial expression of PTEN and, optionally, SMAD4, CD44, and/or TP53 in colonic tumors are described. The methods and kits are useful for identifying a cancer stem cell (CSC)-like zone within a colonic tumor, identifying an adenoma-adenocarcinoma (Ad-ACA) transition zone in a colorectal cancer (CRC) tumor, identifying a CRC tumor that contains high-grade adenoma and/or early adenocarcinoma regions, identifying CSCs in a CRC tumor, diagnosing a subject with high-grade colon adenoma and/or early adenocarcinoma, and determining the likelihood that a colonic tumor in a subject will undergo invasive transformation if left untreated.

公开(公告)号：US20240310388A1

公开(公告)日：2024-09-19

申请号：US18608576

申请日：2024-03-18

Applicant: AMGEN INC.

Inventor： HUIBIN YUE

IPC: G01N33/68 ,  A61K31/445

CPC classification number: G01N33/6893 ,  A61K31/445 ,  G01N2333/521 ,  G01N2333/525 ,  G01N2333/5421 ,  G01N2800/20 ,  G01N2800/52 ,  G01N2800/56

Abstract: The present disclosure provides diagnostic methods, that may be combined with medical treatment, using one or more plasma biomarkers that are useful for identifying a subject with Hidradenitis Suppurativa (HS), measuring disease severity of HS, and measuring clinical response in subjects with HS.

公开(公告)号：US20240295553A1

公开(公告)日：2024-09-05

申请号：US18424298

申请日：2024-01-26

Applicant: Laboratory Corporation of America Holdings

Inventor： Paul Scott Eastman ,  Eric Sasso

IPC: G01N33/564 ,  C12Q1/6883 ,  G09B7/00 ,  G16B40/00 ,  G16B40/20

CPC classification number: G01N33/564 ,  C12Q1/6883 ,  G09B7/00 ,  G16B40/20 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N2800/102 ,  G01N2800/56 ,  G01N2800/60 ,  G16B40/00

Abstract: Biomarkers useful for assessing inflammatory disease or flare activity, in particular in juvenile idiopathic arthritis, are provided, along with kits for measuring expression of the biomarkers. The invention also provides predictive models, based on the biomarkers, as well as computer systems, and software embodiments of the models for scoring and optionally classifying samples.

公开(公告)号：US20240277803A1

公开(公告)日：2024-08-22

申请号：US18439331

申请日：2024-02-12

Applicant: Minerva Biotechnologies Corporation

Inventor： Cynthia Bamdad ,  Benoit Smagghe

IPC: A61K38/17 ,  A01K67/0271 ,  A61K38/45 ,  A61K39/395 ,  A61K49/00 ,  A61P35/00 ,  C07K14/47 ,  C07K16/18 ,  C07K16/30 ,  C07K16/40 ,  C12N9/12 ,  G01N33/50 ,  G01N33/574

CPC classification number: A61K38/1735 ,  A61P35/00 ,  A01K67/0271 ,  A01K2267/0331 ,  A61K38/45 ,  A61K39/3955 ,  A61K49/0008 ,  C07K14/4727 ,  C07K16/18 ,  C07K16/3092 ,  C07K16/40 ,  C12N9/1229 ,  C12Y207/04006 ,  G01N33/5073 ,  G01N33/574 ,  G01N2333/71 ,  G01N2500/10 ,  G01N2800/56

Abstract: The present application discloses inhibitors of NME family of proteins.

公开(公告)号：US20240264177A1

公开(公告)日：2024-08-08

申请号：US18637770

申请日：2024-04-17

Applicant: BANYAN BIOMARKERS, INC.

Inventor： Kevin Ka-Wang WANG ,  Ronald L. HAYES ,  Uwe R. MUELLER ,  Zhiqun ZHANG

IPC: G01N33/68 ,  A61B5/00 ,  G01N33/577

CPC classification number: G01N33/6896 ,  A61B5/4064 ,  G01N33/577 ,  G01N2800/28 ,  G01N2800/2871 ,  G01N2800/52 ,  G01N2800/56 ,  G01N2800/60

Abstract: A robust, quantitative, and reproducible process and assay for diagnosis of a neurological condition in a subject. The method includes measurement of two or more biomarkers in a biological fluid such as CSF or serum resulting in a synergistic mechanism for determining the extent of neurological damage in a subject with an abnormal neurological condition and for discerning subtypes thereof or tissue types subjected to damage.

公开(公告)号：US12044683B2

公开(公告)日：2024-07-23

申请号：US16964437

申请日：2019-01-25

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  UNIVERSITY OF FLORIDA RESEARCH FOUNDATION

Inventor： Ali Zarrinpar

IPC: G01N33/58 ,  A23L5/47 ,  G01N21/31 ,  G01N30/72 ,  G01N30/02

CPC classification number: G01N33/58 ,  A23L5/47 ,  G01N21/31 ,  G01N30/7233 ,  A23V2002/00 ,  G01N2030/027 ,  G01N2800/06 ,  G01N2800/56

Abstract: Methods, assays and compositions for measuring intestinal permeability in subjects are provided. The methods and assays comprise the measurement of the level of food dyes, such as FD&C Blue No. 1, in blood samples shortly after the ingestion of the compositions. The methods disclosed herein are simple, cost-effective, reproducible and sensitive.

公开(公告)号：US11971411B2

公开(公告)日：2024-04-30

申请号：US16071289

申请日：2017-01-20

Applicant: DANA-FARBER CANCER INSTITUTE, INC. ,  PRESIDENT AND FELLOWS OF HARVARD COLLEGE

Inventor： Curtis Huttenhower ,  Travis Gerke ,  Christopher Sweeney ,  Lorelei Mucci ,  Gwo-Sho Mary Lee ,  Daniela Bornigen ,  Xiaodong Wang ,  Svitlana Tyekucheva ,  Kristina Jordahl

IPC: C12Q1/68 ,  G01N33/574

CPC classification number: G01N33/57434 ,  G01N2333/4703 ,  G01N2800/54 ,  G01N2800/56

Abstract: The present invention provides methods for screening and diagnosing prostate cancer based on a correlation between cancer cell growth, cancer lethality or recurrence and the expression level of ZFP36 or NEDD9 and PTEN in conjunction with ZFP36. The disclosure also provides methods for screening and diagnosing prostate cancer based on a correlation between cancer lethality and the genotype of rs1910301 SNP. Also provided are methods for treating prostate cancer comprising providing a treatment or monitoring based on the expression level of ZFP36, the expression level of NEDD9, and the expression level of ZFP36 in conjunction with PTEN levels or the genotype of rs1910301 SNP.

公开(公告)号：US20240110928A1

公开(公告)日：2024-04-04

申请号：US18474826

申请日：2023-09-26

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Saul Datwyler ,  Raj Chandran

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  G01N2333/916 ,  G01N2800/28 ,  G01N2800/56

Abstract: Disclosed herein are methods for aiding in the diagnosis and evaluation of a subject (e.g., a human subject) that has sustained or may have sustained an injury to the head, such as to determine whether the subject is suffering from a mild or a supermild traumatic brain injury.

公开(公告)号：US11913959B2

公开(公告)日：2024-02-27

申请号：US17207412

申请日：2021-03-19

Applicant: Memorial Sloan Kettering Cancer Center

Inventor： Larry Norton ,  Ross Levine ,  Maria Kleppe ,  Elizabeth Comen

IPC: C12Q1/6886 ,  G01N33/574 ,  C07K16/28 ,  A61K31/7068 ,  A61K31/7052 ,  A61K31/52 ,  A61K31/573 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/506 ,  A61K38/17 ,  A61K39/395 ,  A61K45/06 ,  A61K31/00

CPC classification number: G01N33/57484 ,  A61K31/506 ,  A61K31/52 ,  A61K31/573 ,  A61K31/704 ,  A61K31/7048 ,  A61K31/7052 ,  A61K31/7068 ,  A61K38/177 ,  A61K39/3955 ,  A61K45/06 ,  C12Q1/6886 ,  G01N33/57496 ,  A61K31/00 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N2800/52 ,  G01N2800/56 ,  G01N2800/7028

Abstract: Provided herein are methods of treating a nonhematopoietic malignant tumor in a patient and methods of prognosing a nonhematopoietic malignant tumor in a patient, comprising administering to the patient a therapeutically effective amount of an agent that preferentially kills or inhibits proliferation or activity of leukocytes relative to nonhematopoietic cells.